Nascent Biotech Inc (NBIO OTCQB) stock market data APIs
$0.0004
0(0%)
as of June 30, 2025
Try our APIs with
free plan!
Nascent Biotech Inc Financial Data Overview
Price chart is built with
Anychart
Nascent Biotech, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer. It is developing Pritumumab, a drug to treat patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma, as well as epithelial cancers, including lung, breast, colon, brain, and pancreas cancer. The company is developing MultiPharm, a proprietary technology platform for cancer therapy, as well as diabetes, autoimmunity, and transplantation. In addition, it develops CLNH5. Nascent Biotech, Inc. is based in North Palm Beach, Florida.
Prev. Close
0.0004
Open
0.0004
High
0.0004
Low
0.0004
52 wk Range
0.0001-0.0952
Market Cap
68 887
Shares Outstanding
172 M
EPS
-0.0015
Beta
-3.246
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Nascent Biotech Inc data using free add-ons & libraries
Get Nascent Biotech Inc Fundamental Data
Nascent Biotech Inc Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2024-09-30
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Nascent Biotech Inc News
New
Nascent Biotech Officers Convert Liability to Stock in the Company
SAN DIEGO, July 08, 2020 (GLOBE NEWSWIRE) -- Nascent Biotech, Inc. (OTC: NBIO) Announced today that its Senior Officers have converted the Company’s liability to them into common stock, reducing t...
Nascent Biotech Appoints Chief Medical Consultant in Charge of COVID-19 Research
SAN DIEGO, June 24, 2020 (GLOBE NEWSWIRE) -- Nascent Biotech, Inc. (OTC: NBIO) announced today that it has appointed Dr. Navpaul Singh MD as Chief Medical Consultant in charge of research into Pritu...
Nascent Biotech to Begin Animal Model Studies for Pritumumab Against Coronaviruses and COVID-19
SAN DIEGO, June 17, 2020 (GLOBE NEWSWIRE) -- Nascent Biotech, Inc. (OTCQB: NBIO), today announced after receiving early In-Vitro study results Pritumumab, (PTB), will be advanced to laboratory-based...
Nascent Biotech to begin Phase 1 Human Trials for Brain Cancer Drug
SAN DIEGO, May 27, 2020 (GLOBE NEWSWIRE) -- Nascent Biotech, Inc (OTCQB: NBIO) (the “Company” or “Nascent”) is pleased to announce that the Company will soon begin Phase 1 clinical trials ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
